Related Experiment Videos
Famotidine does not inhibit liver regeneration
1Department of Surgery I, Oita Medical College, Japan.
Summary
Famotidine, a new H2-receptor antagonist, does not inhibit liver regeneration in rats after hepatectomy. Instead, famotidine treatment enhanced hepatocyte mitosis and preserved albumin synthesis, unlike other H2-blockers.
Area of Science:
- Hepatology
- Pharmacology
- Regenerative Medicine
Background:
- H2-receptor antagonists like cimetidine and ranitidine have been shown to inhibit liver regeneration.
- Understanding the impact of newer H2-receptor antagonists on liver regeneration is crucial for patient care.
Purpose of the Study:
- To investigate the effects of famotidine, a potent H2-receptor antagonist, on liver regeneration following partial hepatectomy in rats.
- To compare the regenerative response in famotidine-treated rats with control groups.
Main Methods:
- A two-thirds hepatectomy was performed on rats, divided into control and famotidine-treated groups.
- Famotidine was administered intramuscularly at doses of 0.8 mg/kg and 1.2 mg/kg post-operation.
- Liver histology, mitotic index, and serum levels of aminotransferase and albumin were assessed over 10 days.
Main Results:
- Famotidine treatment did not inhibit hepatocyte mitosis.
- A significant increase in the mitotic index was observed on day 3 in famotidine-treated groups compared to controls.
- Serum albumin levels were well-maintained in rats treated with famotidine.
Conclusions:
- Famotidine does not inhibit liver regeneration and may even promote it.
- These findings differentiate famotidine from other H2-receptor antagonists regarding their effects on liver regeneration.
- Famotidine appears to be a safe option for patients with liver conditions requiring H2-receptor blockade.